Cannabis and Cannabinoid Research最新文献

{"title":"Oral Consumption of Cannabidiol During Pregnancy Alters Behavior in Mouse Offspring.","authors":"Luis E Gomez Wulschner, Victoria N Chang, Won Chan Oh, Emily Anne Bates","doi":"10.1177/25785125251413416","DOIUrl":"https://doi.org/10.1177/25785125251413416","url":null,"abstract":"<p><strong>Background: </strong>Pregnant people use cannabidiol (CBD) to treat nausea, insomnia, anxiety, and pain. However, CBD crosses the placenta and enters the fetal brain, where it can affect several targets important for brain development. While consumption of high doses of CBD during pregnancy has been shown to disrupt offspring neurodevelopment, pain sensitivity, and cognitive behavior in mice, lower doses have not been assessed.</p><p><strong>Methodology: </strong>We administered 10 mg/kg/day CBD by oral gavage to pregnant C57Bl6 mice from embryonic day 5 through birth. We used the puzzle box, the forced swim test, and Hargreaves thermal sensitivity behavior tests and electrophysiology to determine how prenatal CBD exposure affects postnatal behavior and prefrontal cortex physiology.</p><p><strong>Results: </strong>We show that oral consumption of 10 mg/kg/day CBD during pregnancy increases thermal pain sensitivity in male mouse offspring. Furthermore, the same dose impairs cognition and reduces excitability of the prefrontal cortex in female mouse offspring.</p><p><strong>Conclusion: </strong>These data show that lower doses of CBD consumption during pregnancy can impair fetal brain development and postnatal behavior.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":"11 2","pages":"130-137"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Medical Marijuana Cardholder Status and Antiemetic Overuse.","authors":"Alan P Baltz, Cheng Peng, Laura Gressler, Sajjad Bhatti, Kanna Lewis","doi":"10.1089/can.2024.0083","DOIUrl":"10.1089/can.2024.0083","url":null,"abstract":"<p><strong>Introduction: </strong>The conscientious prescribing of antiemetics by chemotherapy-induced nausea and vomiting (CINV) risk was highlighted in the American Society of Clinical Oncology (ASCO) \"Choosing Wisely\" recommendations. The pharmacologic properties of medical marijuana (MMJ) may allow for decreased incidence of CINV; however, little is known about the effects of MMJ on the use of antiemetics. This study aimed to determine if MMJ cardholder status, which enables access to MMJ, is associated with antiemetic overuse among patients with cancer.</p><p><strong>Materials and methods: </strong>This population-based secondary data analysis examined a retrospective cohort derived from the linked Arkansas All Payers Claims Database (2013-2020) and MMJ cardholder registry (2013-2019). The cohort consisted of 20,558 patients with cancer aged 18 and older with a chemotherapy claim in an outpatient setting within 12 months of a cancer diagnosis. Exposure was a registration to receive an MMJ card that permitted access to MMJ. The primary outcome of interest was antiemetic overuse, as characterized by the ASCO recommendation. Antiemetic use associated with chemotherapy was identified through filled prescriptions and medical claims. Multivariable logistic regression, adjusted for baseline demographic and prescription characteristics, was used to calculate the adjusted odds ratios (aOR) of antiemetic overuse among MMJ cardholders compared with non-MMJ cardholders.</p><p><strong>Results: </strong>Among 20,558 eligible patients, 436 (2.1%) had an MMJ card at some point in the study period. Antiemetic overuse was identified in 7.5% of chemotherapy cycles. Compared with non-MMJ cardholders, MMJ cardholders were less likely to experience antiemetics overuse (aOR: 0.76, <i>p</i> < 0.001). Patients with fewer chemotherapy cycles and younger in age had higher odds of antiemetic overuse compared with those with more chemotherapy cycles. The risk of antiemetic overuse did not differ based on gender and rurality of residency. Route of chemotherapy administration, CINV risk category, and type of cancer also impacted the odds of antiemetic overuse.</p><p><strong>Discussion: </strong>The findings indicate that MMJ cardholders are significantly less likely to experience antiemetic overuse than non-MMJ cardholders. Further investigation into the use, effectiveness, and safety of cannabis for CINV mitigation is needed to inform patient and provider decision-making.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"180-188"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Cannabis Research in a Changing Landscape: Meeting Summary of the 2025 California Cannabis Research Workshop.","authors":"Margarete C Kulik, Hilda Vasquez, Tracy Richmond McKnight, Agnes Balla","doi":"10.1177/25785125261417167","DOIUrl":"10.1177/25785125261417167","url":null,"abstract":"<p><p>On March 25, 2025, the University of California Office of the President, in partnership with the California Department of Cannabis Control, hosted the 2025 California Cannabis Research Workshop in Sacramento, CA. Building on prior gatherings in 2019, 2021, and 2023, the 2025 California Cannabis Research Workshop sought to strengthen collaboration between researchers and state policymakers during a time when the federal regulatory and scientific landscape is rapidly evolving. The event featured discussions on the role of state agencies supporting cannabis research, applications of cannabis research funding, strategies for accessing varied cannabis research products, innovations in agrarian research, and examples of state support for research. The 2025 workshop provided a platform for exploring how cannabis research can inform public policy and address emerging scientific and societal questions despite uncertainties arising from the federal landscape.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"125-129"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147302585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Interactions in People on Cannabidiol: Is There Cause for Concern?","authors":"Georgia Downs, Ristan Greer, Geraldine Moses, Taylan Gurgenci, Phillip Good, Janet Hardy","doi":"10.1089/can.2024.0041","DOIUrl":"10.1089/can.2024.0041","url":null,"abstract":"<p><strong>Introduction: </strong>Cannabidiol (CBD) exhibits multiple therapeutic properties, but its use in advanced cancer patients raises concerns about potential drug-drug interactions (DDIs) due to polypharmacy. This study aims to look for evidence of DDIs between concomitant medications and CBD oil in a randomized placebo-controlled trial of CBD oil for symptom control (MedCan-1 parent study).</p><p><strong>Materials and methods: </strong>Surrogate measures were used to identify possible drug interactions: (1) the maximum mL of oil self-selected by patients in CBD or placebo groups in relation to opioids, specific drug groups, or individual agents; (2) the occurrence of any new or worse adverse effect in relation to the study arm and the concomitant medication classes/medications of interest.</p><p><strong>Results: </strong>The dose of CBD self-selected by participants was not related to opioid use or medications, including benzodiazepines and antipsychotics. The likelihood of developing an adverse effect while on study or when taking specific medications was not increased by CBD. Participants on paracetamol tolerated a higher dose of CBD.</p><p><strong>Discussion: </strong>Concerns regarding the development of clinically significant drug interactions when taking CBD in the context of anti-cancer and other concomitant medications at least in the short term may be unfounded.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"138-146"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis Provenance by Isotope Ratio Analysis.","authors":"Crist N Filer","doi":"10.1177/25785125251390646","DOIUrl":"10.1177/25785125251390646","url":null,"abstract":"","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"97-98"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145298581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study.","authors":"Taylor R Ewell, Matthew C Bomar, Kieran S S Abbotts, Brendan T Kayne, Briana D Risk, Natasha N B Williams, Yuren Wei, Gregory P Dooley, Tiffany L Weir, Christopher Bell","doi":"10.1177/25785125251391085","DOIUrl":"10.1177/25785125251391085","url":null,"abstract":"<p><strong>Introduction: </strong>Epidemiological data indicate that regular users of cannabis products may be protected from type 2 diabetes, although the mechanism is not understood. Observations from animal studies suggest that the cannabinoid, cannabidiol (CBD) may protect/improve glucose tolerance; an effect that may be partially mediated by favorable modifications to the gut microbiome. The aims of the current pilot project were to gain initial insight into the influence of short-term CBD ingestion on oral glucose tolerance, the gut microbiome, and inflammation in sedentary adults with overweight or obesity and free from diabetes.</p><p><strong>Materials and methods: </strong>Using a randomized, double-blind, repeated measures, parallel design, oral glucose tolerance was determined in 16 adults (6 males, 10 females) prior to and following 4 weeks of daily ingestion of either placebo or CBD (30 mg every 12 h). Fecal samples were collected at baseline and post-intervention.</p><p><strong>Results: </strong>Compared with placebo, CBD did not influence glucose tolerance (Matsuda Index: placebo-pre 7.6 [5.5], placebo-post 10.1 [5.5], <i>vs</i>. CBD-pre 11.7 [7.9], and hCBD-post 10.1 [10.2]; median [interquartile range]; <i>p</i> > 0.05). Characteristics of the gut microbiome or inflammation were not appreciably modified by CBD or placebo.</p><p><strong>Discussion: </strong>Short-term daily ingestion of low-dose CBD did not appear to favorably modify glucose tolerance in sedentary adults with overweight or obesity. It is possible that CBD may not account for the previously reported protection from type 2 diabetes bestowed to regular users of cannabis products.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"147-159"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145408123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations Between Cannabis Use and Inflammatory Biomarkers Among People with HIV.","authors":"Stephanie A Ruderman, Joseph A C Delaney, Kristina A Crothers, Engi F Attia, Bridget M Whitney, Sonia Napravnik, Laura Bamford, Michael S Saag, Richard D Moore, Kenneth H Mayer, Inga Peter, Amelia Deitchman, Carl Grunfeld, Fang Fang, Mari M Kitahata, Heidi M Crane, Peter W Hunt","doi":"10.1177/25785125261437619","DOIUrl":"10.1177/25785125261437619","url":null,"abstract":"<p><strong>Background: </strong>We explored whether self-reported current cannabis use is associated with inflammatory biomarkers among people with HIV (PWH), given high rates of cannabis use and chronic immune activation among PWH.</p><p><strong>Methods: </strong>At seven Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort sites, which integrate data on participant characteristics including demographic and clinical information, and substance use behaviors, we used linear regression to estimate the average difference in biomarkers associated with cannabis use, adjusted for demographic characteristics and sampling weights. Cannabis use was considered as Never, Former, or Current (past 3-month) use. Thirteen plasma biomarkers were measured once on or after 2010 among a subset of PWH on antiretroviral therapy with HIV viral suppression within CNICS. Cannabis use was assessed within 1 year prior to biomarker collection. Biomarkers were log-transformed and scaled by standard deviation to standardize estimates.</p><p><strong>Results: </strong>Among 532 PWH, the average age at biomarker collection date was 47 years, 84% were male, 61% non-White, 30% reported current cannabis use, 35% former use, and 35% never using cannabis. In adjusted linear regression, current cannabis use was associated with higher soluble CD14 (sCD14) levels (β = 0.35; 95% confidence interval [CI]: 0.09, 0.61). Former cannabis use was associated with lower C-reactive protein (CRP) (β = -0.25; 95% CI: -0.47, -0.04), although current use was not (β = -0.25; 95% CI: -0.51, 0.01) compared to never use.</p><p><strong>Conclusions: </strong>Cannabis use may be related to lower CRP and elevated markers of microbial translocation (e.g., sCD14), which could have implications in increasing the risk of vascular events and should be investigated in a longitudinal setting.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"25785125261437619"},"PeriodicalIF":2.7,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Exogenous Cannabinoids in Pre-Clinical Models of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.","authors":"Shijia Wang, Xiaocong Lin, Fanglian Liao, Yifeng Liang, Cailuan Wang, Liming Gan","doi":"10.1177/25785125261428842","DOIUrl":"10.1177/25785125261428842","url":null,"abstract":"<p><strong>Background: </strong>Exogenous cannabinoids are considered promising therapeutic candidates for inflammatory bowel disease (IBD). However, robust pre-clinical evidence supporting its efficacy remains limited. This systematic review and meta-analysis aimed to evaluate the therapeutic effects of exogenous cannabinoids in animal models of IBD.</p><p><strong>Methods: </strong>Controlled experimental studies involving animal models of IBD that evaluated the effects of exogenous cannabinoids compared to untreated models were included. Four databases (PubMed, Embase, Web of Science, and the Cochrane Library) were searched up to August 26, 2025. Two independent reviewers conducted study selection, data extraction, and the risk-of-bias assessment. The risk-of-bias assessment was performed using the Systematic Review Center for Laboratory Animal Experimentation tool. Meta-analyses were performed using standardized mean differences (SMDs) and random-effects models. The study was registered in INPLASY (INPLASY202540009).</p><p><strong>Results: </strong>Twenty-seven pre-clinical studies involving 408 animals were included. Compared with controls, exogenous cannabinoids significantly reduced disease activity index (SMD = -3.43; 95% confidence interval [CI]: -4.98 to -1.89; <i>I</i>² <i>=</i> 83%) and histopathological score (SMD = -4.46; 95% CI: -6.37 to -2.54; <i>I</i>² <i>=</i> 84%). It also decreased levels of myeloperoxidase (MPO), TNF-α, IL-6, and IL-1β. However, substantial heterogeneity was noted across several outcomes.</p><p><strong>Interpretation: </strong>Exogenous cannabinoids show beneficial effects in pre-clinical IBD models, likely through anti-inflammatory, antioxidant, and barrier-enhancing mechanisms. These findings provide a supportive foundation for future translational research. Nevertheless, the overall certainty of the evidence is limited by unclear randomization, lack of blinding, high heterogeneity, and small sample sizes. Although some clinical trials have already begun exploring its therapeutic potential, further rigorous and standardized animal studies are needed to clarify mechanisms, optimize dosing, and reinforce the translational pathway.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"25785125261428842"},"PeriodicalIF":2.7,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabinoid Hyperemesis Syndrome-A Survey-Based Approach to Understanding Symptoms and Cannabis Use Patterns.","authors":"Codi Peterson, Jill Simonian, Megan Mbengue, Jacqueline Higgins, Riley Kirk, Katie Nava, Ryan Lacinski, Ariana Nelson","doi":"10.1177/25785125261421434","DOIUrl":"https://doi.org/10.1177/25785125261421434","url":null,"abstract":"<p><strong>Background: </strong>Cannabinoid hyperemesis syndrome (CHS) is increasingly being observed in emergency departments and is characterized by recurrent nausea and vomiting in some cannabis users. Despite its increasing prevalence, tools for early identification and intervention are lacking. This study aimed to improve our understanding of CHS by examining patterns of cannabis use and identifying symptom profiles of individuals suspected or diagnosed with CHS. By identifying the risk factors and initial warning signs, we can support earlier recognition, harm reduction, and intervention.</p><p><strong>Materials and methods: </strong>An anonymous survey was distributed via social media to gather detailed, self-reported information about cannabis consumption methods, frequency of use, product sourcing, and CHS-related symptoms. Participants were recruited online through organic outreach to CHS-focused social media communities in late 2024.</p><p><strong>Results: </strong>A total of 1134 participants were included in the final analysis. Most respondents reported smoking cannabis flower or using vape cartridges, although the use of edibles and concentrates were also described. The overwhelming majority of respondents (96.5%) used cannabis products at least daily, with approximately half (45%) using them six or more times per day around the time they developed CHS symptoms. Most of the respondents (61.9%) sourced cannabis from licensed dispensaries. The duration of cannabis use prior to symptom onset varied widely among participants, with nearly two-thirds (65.4%) reportedly used for more than 3 years before symptom development. During the prodromal (early) phase, symptoms clustered in the morning (63.1%) and the predominant complaints were nausea and stomach pain. Women reported more frequent and prolonged symptoms than men.</p><p><strong>Discussion: </strong>Our findings suggest that CHS is most associated with long-term, frequent use of inhaled delta-9-tetrahydrocannabinol (Δ9-THC) dominant cannabis. The acquisition source of cannabis products did not affect the syndrome presentation. Although many different cannabis consumption methods were represented, smoking and vape cartridges were the most commonly reported. The use of vape cartridges was associated with a shorter time to the development of CHS symptoms. Increased awareness of these patterns could improve the early recognition and management of CHS.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"25785125261421434"},"PeriodicalIF":2.7,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147353920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regular Cannabis Use is Associated with a Diminished Anandamide Response to a Standard Exercise Stimulus: A Pilot Study.","authors":"Taylor R Ewell, Matthew C Bomar, Kate E Green, Vanessa T Stallsmith, Gregory P Dooley, Christopher Bell, Hollis C Karoly","doi":"10.1177/25785125261428008","DOIUrl":"https://doi.org/10.1177/25785125261428008","url":null,"abstract":"<p><strong>Introduction: </strong>The endocannabinoid system (ECS) is increasingly recognized as an important regulator of many physiological systems. People who use products derived from <i>Cannabis sativa</i> L. are exposed to exogenous cannabinoids. The influence of this exogenous exposure on the ECS is unclear. People who use cannabis have demonstrated lower basal levels of endocannabinoids, but the dynamic response of their ECS to a controlled stimulus is unknown. Our study purpose was to compare circulating concentrations of the endocannabinoid <i>N</i>-arachidonoylethanolamine (anandamide, AEA) and subjective experiences between people who use cannabis and those who do not, during and following a standardized exercise stimulus.</p><p><strong>Materials and methods: </strong>Twenty adults (<i>n</i> = 8 who regularly use cannabis [age: 21-32 years; 5/3 males/females] and <i>n</i> = 12 who do not use cannabis [age: 21-39 years; 7/5 males/females]) completed a 1-h treadmill run at an intensity equivalent to 65% of peak oxygen uptake. Arterialized-venous blood was collected prior to, during (including the last minute of exercise), and 15 min following exercise for determination of anandamide concentration. The subjective experiences of the participants during and after the run were assessed with responses to several questions assessed on a Likert scale.</p><p><strong>Results: </strong>Compared with controls, the cannabis use group had lower AEA concentrations at end-exercise (0.47 ± 0.13 vs. 0.33 ± 0.10 ng/mL; <i>p</i> = 0.015) and 15-min post-exercise (0.57 ± 0.17 vs. 0.38 ± 0.18 ng/mL; <i>p</i> = 0.001). The cannabis use group also had worse mood (3.25 ± 1.03 <i>vs.</i> 2.29 ± 1.34; main effect of condition <i>p =</i> 0.05) and higher probability of feeling pain (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Habitual cannabis use was associated with diminished AEA response, worse mood, and more pain during/following exercise. These pilot data might have implications for clinical outcomes associated with cannabis use, including cannabis use disorder and withdrawal, as well as potentially for exercise adherence.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"25785125261428008"},"PeriodicalIF":2.7,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}